NEWS
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
Elevai Labs, Inc. (NASDAQ: ELAB) has announced positive results from a clinical study of its Elevai enfinity™ topical exosome serum. The 12-week study, conducted on 29 participants aged 40-70 with mild to moderate facial photoaging and sensitive skin, showed the product to be safe and tolerable with significant improvements in various aspects of skin appearance.
The study, led by renowned dermatologist Dr. Zoe Draelos, assessed the twice-daily use of Elevai enfinity™ on facial firmness, skin tone, wrinkles, and smoothness. CEO Dr. Jordan R. Plews emphasized the importance of this rigorous study in validating the product's effectiveness. Elevai plans to publish the full study results soon and continues to prioritize scientific research as part of its commercial strategy for 2024 and beyond.
The study, led by renowned dermatologist Dr. Zoe Draelos, assessed the twice-daily use of Elevai enfinity™ on facial firmness, skin tone, wrinkles, and smoothness. CEO Dr. Jordan R. Plews emphasized the importance of this rigorous study in validating the product's effectiveness. Elevai plans to publish the full study results soon and continues to prioritize scientific research as part of its commercial strategy for 2024 and beyond.
免責聲明：社區由Moomoo Technologies Inc.提供，僅用於教育目的。
更多信息
評論
登錄發表評論
